Frontage, a full service CRO with operations in the U.S. and China, is expanding its bioanalytical laboratories for small molecules, large molecules and biologics, including the bioanalysis of Antibody Drug Conjugates (ADCs) by mass spectroscopy and ligand binding platforms.
 
Frontage has completed an expansion of its Exton, PA operations with an additional 10,000 sq.-ft. of labs, allowing for the installation of 20 additional mass spectrometers, including the SCIEX TripleTOF 6600 System for the measurement of peptides, antibodies and ADCs, and four SCIEX Triple Quad 6500 Systems, bringing the number of MS systems to more than 50 globally.
 
The expansion also increases the site’s deep freezer capacity to 32 -70 °C freezers, equipped with emergency backup power generation. The company also added labs that expand its biologics service offerings for ECL and ELISA-based assays, as well as its DMPK operations supporting discovery-stage pharmacokinetics and development-stage metabolism studies.
 
“Frontage’s expansion of our bioanalytical and DMPK operations is an essential step of meeting our client’s expectations to provide high quality services efficiently and economically. It is very exciting to see our company grow to meet these demands and have the ability to add some great people to our teams. We have also invested in equipment that will allow us to remain at the forefront of drug development and enable us to analyze increasingly complex new drug candidates. We are thankful for all of the clients that have put their trust in Frontage and for our team members who continue to perform at a high level,” said Dr. Song Li, chief executive officer of Frontage.